Protection of CD95-mediated apoptosis by activation of phosphatidylinositide 3-kinase and protein kinase B - PubMed (original) (raw)

Protection of CD95-mediated apoptosis by activation of phosphatidylinositide 3-kinase and protein kinase B

P Häusler et al. Eur J Immunol. 1998 Jan.

Free article

Abstract

Apoptosis may be triggered, in a variety of tissues, by interaction of the cell surface molecule CD95 with its specific ligand, CD95L. CD95 plays a physiological role in the regulation of the immune response; furthermore, alterations in CD95/CD95L function may contribute to the pathogenesis of a number of human diseases, including cancer, autoimmune diseases and viral infections. Many cells that express CD95, however, are not susceptible to CD95-mediated apoptosis. It is therefore important to identify the mechanisms that counteract the CD95 apoptotic process that are still poorly understood. Growth factors and lymphokines such as interleukin (IL)-4 that counteract CD95-mediated apoptosis may activate phosphatidylinositide 3-kinase (PI 3-kinase). We therefore used two different approaches to investigate the role of PI 3-kinase on CD95-mediated apoptosis. First we tested the effect of two pharmacological PI 3-kinase inhibitors, wortmannin and LY294002, on CD95 agonistic antibody-induced apoptosis in three different cell lines. Second, we co-expressed in COS7 cells CD95 with constitutively active PI 3-kinase. Results of both approaches indicate that active PI 3-kinase effectively protects against CD95-mediated apoptosis. Furthermore we extended our studies on the CD95 downstream mediator, FADD, and on the PI 3-kinase downstream mediator, the serine/threonine protein kinase PKB, using the co-expression approach in COS7 cells. We provide evidence that apoptosis induced by triggering the CD95 cell death receptor is counteracted by PI 3-kinase activation; moreover, PKB but not p70S6K represents the relevant downstream target of PI 3-kinase signaling.

PubMed Disclaimer

Cited by

Protein kinase B regulates T lymphocyte survival, nuclear factor kappaB activation, and Bcl-X(L) levels in vivo.
Jones RG, Parsons M, Bonnard M, Chan VS, Yeh WC, Woodgett JR, Ohashi PS. Jones RG, et al. J Exp Med. 2000 May 15;191(10):1721-34. doi: 10.1084/jem.191.10.1721. J Exp Med. 2000. PMID: 10811865 Free PMC article.
Conditional drug screening shows that mitotic inhibitors induce AKT/PKB-insensitive apoptosis.
Berndtsson M, Hernlund E, Shoshan MC, Linder S. Berndtsson M, et al. J Chem Biol. 2009 Jun;2(2):81-7. doi: 10.1007/s12154-009-0017-7. Epub 2009 Mar 31. J Chem Biol. 2009. PMID: 19568785 Free PMC article.
AKT controls human first trimester trophoblast cell sensitivity to FAS-mediated apoptosis by regulating XIAP expression.
Straszewski-Chavez SL, Abrahams VM, Aldo PB, Romero R, Mor G. Straszewski-Chavez SL, et al. Biol Reprod. 2010 Jan;82(1):146-52. doi: 10.1095/biolreprod.109.078972. Epub 2009 Sep 2. Biol Reprod. 2010. PMID: 19726736 Free PMC article.
Palmitoylation of CD95 facilitates formation of SDS-stable receptor aggregates that initiate apoptosis signaling.
Feig C, Tchikov V, Schütze S, Peter ME. Feig C, et al. EMBO J. 2007 Jan 10;26(1):221-31. doi: 10.1038/sj.emboj.7601460. Epub 2006 Dec 7. EMBO J. 2007. PMID: 17159907 Free PMC article.

Protection of CD95-mediated apoptosis by activation of phosphatidylinositide 3-kinase and protein kinase B - PubMed (original) (raw)